The global RNAi market is categorized based on various types of drug delivery technologies and by therapeutic application. The drug delivery segment is further sub-segmented into nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology. Nanoparticle drug delivery technology is the largest sub-segment in global RNAi drug delivery market. However, aptamer drug delivery technology is the fastest growing sub-segment in global RNAi drug delivery market.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3511
RNAi is one of the most important methods of analyzing gene functions in eukaryotes. It also plays a pivotal role in development of therapeutic gene silencing. Gene silencing is a term refers to the ability of a cell to prevent the expression of a specific gene.
RNAi has application in the areas of therapeutics, drug delivery, research and development and agriculture. The therapeutics application of RNAi includes metabolic disorders, cardiology, neurology, oncology and ophthalmology.
Therapeutic segment includes infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders.
In terms of geographic, North America and Europe dominates the global RNAi drug delivery market. This is due to improved life science research infrastructures in these regions. The U.S. represents the largest market for RNAi drug delivery technologies followed by Canada in North America. In Europe, France, Germany, Spain and the U.K. holds major share of RNAi drug delivery market. However, Asia is expected to show high growth rates in the next five years in global RNAi drug delivery market due to increased investment by major companies in the region. Japan, China and India are expected to be the fastest growing RNAi drug delivery markets in Asia.
In recent time, increasing prevalence of diseases, such as cancer and cardiovascular diseases, and innovative applications of the drug delivery technologies are some of the major drivers of the global RNAi drug delivery market. For instance, aptamer drug delivery technology offers several advantages compared to protein and small-molecule drugs, such as low risk of side-effects and complications in humans and enhanced their drug like properties including improved stability and residence time in the bloodstream.
In addition, increased research in the field of RNA therapeutics has also fueled the growth of global RNAi drug delivery market. However, high investment cost and stringent regulations are some of the major restraints for the global RNAi drug delivery market. In addition, targeted delivery of RNA molecules is key challenge for the global RNAi drug delivery market. Many companies engaged in developing RNA therapeutics are facing difficulties in delivery of RNA molecules to specific tissues to bring about a therapeutic effect. Increased research in the field of nanotechnology develops opportunity for the global RNAi drug delivery market. Increasing mergers and collaborations between life sciences companies and government research organizations is key trend for the global RNAi drug delivery market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3511
Some of the major companies operating in the global RNAi drug delivery market are Tekmira Pharmaceuticals Corp., Alnylam Pharmaceuticals Inc., Merck & Co. Inc., Isis Pharmaceuticals, Inc, Access Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Marina Biotech Inc., RXi Pharmaceuticals Corp., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Tacere Therapeutics Inc., PhaseRx Inc., Sirnaomics Inc., and Traversa Therapeutics Inc..
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353